Lichen China
LICN
1 hedge funds and large institutions have $30.8K invested in Lichen China in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1,987% more capital inflows, than outflows
Capital inflows: $27.1K | Capital outflows: $1.3K
0.19% more ownership
Funds ownership: 0% → 0.2% (+0.19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$27.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.3K |
LICN Hedge Fund Activity: Q1 2024 in Review
1 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Lichen China (LICN) for Q1 2024, worth a combined $30.8K — up 2,274% from $1.3K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new LICN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $27.1K. The largest seller was UBS Group, cutting an estimated $1.3K.
- 1 institutional investor held Lichen China (LICN) as of Q1 2024, up from 0 in Q4 2023.
- Funds reported $30.8K of Lichen China stock for Q1 2024, up 2,274% quarter-over-quarter.
- 1 fund opened new Lichen China positions in Q1 2024 and 0 closed out, a net change of +1 holder.
- The largest Lichen China buyer in Q1 2024 was Susquehanna International Group, an estimated $27.1K added.
- The largest Lichen China seller in Q1 2024 was UBS Group, an estimated $1.3K sold.
Based on aggregated 13F filings for Q1 2024.